# A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

> **NCT04044950** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Papillomavirus Infections
- Oropharyngeal Neoplasms

## Interventions

- **BIOLOGICAL:** E7 TCR

## Key facts

- **NCT ID:** NCT04044950
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-07-29
- **Primary completion:** 2020-09-17
- **Final completion:** 2020-09-17
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was closed due to investigator discretion based on the lack of ability to recruit patients and research goals of the program.
- **Last updated:** 2020-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044950, "A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04044950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*